Source: FDA, National Drug Code (US) Revision Year: 2018
ANTHRASIL is an Anthrax Immune Globulin Intravenous (Human) indicated for the treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs.
The effectiveness of ANTHRASIL is based solely on efficacy studies conducted in animal models of inhalational anthrax [See 13.2 Animal Toxicology and/or Pharmacology].
Limitations:
For intravenous use only.
Table 1. ANTHRASIL Dosing Guide and Intravenous Infusion Rate:
Patient Group | Dosea | Starting Infusion Rate (first 30 minutes) | Incremental Infusion Rate if Tolerated (every 30 minutes) | Maximum Infusion Rate |
---|---|---|---|---|
Adults ≥17 years | 7 vials (420 units) | 0.5 mL/min | 1 mL/min | 2 mL/min |
Pediatric <1 year to ≤16 years | 1–7 vials (60–420 units) based on patient weight | 0.01 mL/kg/min (do not exceed the adult rate) | 0.02 mL/kg/min | 0.04 mL/kg/min (do not exceed the adult rate) |
a Select initial dose based on clinical severity; severe cases may warrant use of 14 vials (840 units) in adults and 2 to 14 vials (based on weight) in pediatric patients weighing >5 kg.
Table 2. Pediatric Dosing Guide for ANTHRASIL:
Body Weight (kg) | Number of ANTHRASIL Vials per Dose b |
---|---|
<5 | 1 |
<10 | 1 |
10 to <18 | 2 |
18 to <25 | 3 |
25 to <35 | 4 |
35 to <50 | 5 |
50 to <60 | 6 |
≥60 | 7 |
a The pediatric dosing is derived from allometric scaling based on observed adult exposure to ANTHRASIL at 420 units by Toxin Neutralization Assay (TNA) dose.
b Select initial dose based on clinical severity. Dose may be doubled for severe cases in patients >5 kg.
The initial dose of ANTHRASIL for the treatment of inhalational anthrax in adults in combination with appropriate antimicrobial therapy is 420 units (seven vials). Data in animal models suggest that administration of higher doses may result in improved survival [See 13.2 Animal Toxicology and/or Pharmacology]. An initial dose of 840 units (14 vials) may be considered, depending on the clinical status of the patient.
Depending on the severity of symptoms and the response to treatment, consider an initial dose of 840 units (14 vials) and repeat dosing especially in patients experiencing substantial hemorrhage as reflected in large transfusion requirements, patients with significant compartmental fluid losses such as from large volume and/or repeated therapeutic thoracentesis and/or abdominal paracentesis, and in patients whose own immune response may be impaired/delayed. Take the magnitude of ongoing blood and fluid losses and the clinical status of the patient into account in determining the time interval between doses when repeat doses are administered. Repeated dosing and single doses greater than 840 units in humans have not been studied. Without substantially delaying therapy, give consideration to performing therapeutic thoracentesis and/or abdominal paracentesis as indicated prior to or concurrently with administration of ANTHRASIL.
Each vial of ANTHRASIL has a minimum potency of ≥60 units per vial [See 3 DOSAGE FORMS AND STRENGTHS].
Store frozen at or below ≤-15°C (≤5°F) until required for use. Do not use after expiration date.
Once punctured, use the vial contents to prepare the infusion bag and infuse as soon as possible. ANTHRASIL contains no preservative.
Do not refreeze, reuse or save ANTHRASIL for future use.
Discard any partially used vials.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.